Loading
NASDAQHealthcareBiotechnology
Latest quote
$541.08
−$1.53 · -0.28%
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Latest quote
$541.08
−$1.53 · -0.28%
Regular session · ET · Market data may be delayed.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
93
Deep Value
Sentiment
55
Mixed
Risk
33
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 958.4M USD | 180.13M USD | — | — | — |
| Cost of goods sold | 56.15M USD | 6.23M USD | — | — | — |
| Gross profit | 902.26M USD | 173.9M USD | — | — | — |
| Research and development | 388.53M USD | 236.72M USD | 272.35M USD | 245.44M USD | 205.16M USD |
| Selling, general, and administrative | 813.83M USD | 435.06M USD | 108.15M USD | 48.13M USD | 37.32M USD |
| Operating expenses | 1.2B USD | 671.78M USD | 380.5M USD | 293.57M USD | 242.48M USD |
| Interest income | 37.36M USD | 46.65M USD | 19.58M USD | 2.19M USD | 363K USD |
| Interest expense | 22.31M USD | 14.67M USD | 12.71M USD | 3.96M USD | — |
| Depreciation and amortization | 1.51M USD | 1.1M USD | 527K USD | 467K USD | 405K USD |
| Operating income | −300.1M USD | −497.88M USD | −380.5M USD | −293.57M USD | −242.48M USD |
| Net income | −288.28M USD | −465.89M USD | −373.63M USD | −295.35M USD | −241.85M USD |
Company facts updated Sep 5, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$677
25.12% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI274.26M0.01%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB198.2M0.11%183.4B USD0.03%$300.01+0.05%
State Street SPDR S&P Biotech ETFXBI121.92M1.06%11.49B USD0.35%$163.81-0.35%
Vanguard Morningstar Small-Cap Growth ETFVBK114.73M0.26%43.8B USD0.05%$349.44+0.01%
Vanguard Extended Market ETFVXF101.7M0.11%93.7B USD0.05%$242.66+0.14%
First Trust NYSE Arca Biotechnology Index FundFBT91.53M3.07%2.98B USD0.55%$270.93-1.04%
iShares Biotechnology ETFIBB86.9M0.82%10.72B USD0.44%$211.92-0.88%
iShares Russell Mid-Cap Growth ETFIWP54.4M0.28%19.33B USD0.23%$139.69-0.09%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
